Cargando…

MON-LB008 PD-L1 Expression in Normal Endocrine Tissues

Introduction: Immune checkpoint inhibitor (ICI) therapy, including cytotoxic T-lymphocyte-associated protein 4 (CLTA-4) and programmed cell death 1 (PD-1) inhibitors, is revolutionizing cancer treatment. However, these agents are associated with immune-related adverse events (irAEs), most commonly e...

Descripción completa

Detalles Bibliográficos
Autores principales: Pollack, Rena, Kagan, Maayan, Dresner-Pollak, Rivka, Tzahi, Neuman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6550633/
http://dx.doi.org/10.1210/js.2019-MON-LB008
_version_ 1783424224945242112
author Pollack, Rena
Kagan, Maayan
Dresner-Pollak, Rivka
Tzahi, Neuman
author_facet Pollack, Rena
Kagan, Maayan
Dresner-Pollak, Rivka
Tzahi, Neuman
author_sort Pollack, Rena
collection PubMed
description Introduction: Immune checkpoint inhibitor (ICI) therapy, including cytotoxic T-lymphocyte-associated protein 4 (CLTA-4) and programmed cell death 1 (PD-1) inhibitors, is revolutionizing cancer treatment. However, these agents are associated with immune-related adverse events (irAEs), most commonly endocrine-related. Hypophysitis, thyroid dysfunction, insulin-deficient diabetes mellitus and primary adrenal insufficiency have been reported as irAEs due ICI therapy. The precise mechanisms underlying these endocrine irAEs remain to be elucidated. Aim: In this study, we evaluated patterns of programmed cell death ligand 1 (PD-L1) expression in normal endocrine tissues to determine whether increased expression may explain the predilection of endocrinopathies in patients treated with PD-1 inhibitors. Methods: Immunohistochemical (IHC) analysis using the Ventana 22C3 PD-L1 IHC platform was performed on normal FFPE endocrine tissue samples stored in our hospital pathology tissue archive. Results: Five samples from each organ including pituitary, thyroid, parathyroid, adrenal and pancreas were examined. Focal membranous PD-L1 positivity was noted in the normal pituitary tissues, but was negative in normal thyroid, parathyroid, adrenal and pancreatic tissues. Conclusions: Majority of normal endocrine tissues do not demonstrate increased PD-L1 expression. Our limited data so far does not support the hypothesis that increased PD-L1 expression in endocrine tissues is associated with the endocrine irAEs following anti PD-1 therapy. The increased predilection of endocrinopathies in patients treated with anti PD-1 inhibitors seems to be via alternate pathways. Unless otherwise noted, all abstracts presented at ENDO are embargoed until the date and time of presentation. For oral presentations, the abstracts are embargoed until the session begins. Abstracts presented at a news conference are embargoed until the date and time of the news conference. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.
format Online
Article
Text
id pubmed-6550633
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Endocrine Society
record_format MEDLINE/PubMed
spelling pubmed-65506332019-06-13 MON-LB008 PD-L1 Expression in Normal Endocrine Tissues Pollack, Rena Kagan, Maayan Dresner-Pollak, Rivka Tzahi, Neuman J Endocr Soc Endocrine Disruption Introduction: Immune checkpoint inhibitor (ICI) therapy, including cytotoxic T-lymphocyte-associated protein 4 (CLTA-4) and programmed cell death 1 (PD-1) inhibitors, is revolutionizing cancer treatment. However, these agents are associated with immune-related adverse events (irAEs), most commonly endocrine-related. Hypophysitis, thyroid dysfunction, insulin-deficient diabetes mellitus and primary adrenal insufficiency have been reported as irAEs due ICI therapy. The precise mechanisms underlying these endocrine irAEs remain to be elucidated. Aim: In this study, we evaluated patterns of programmed cell death ligand 1 (PD-L1) expression in normal endocrine tissues to determine whether increased expression may explain the predilection of endocrinopathies in patients treated with PD-1 inhibitors. Methods: Immunohistochemical (IHC) analysis using the Ventana 22C3 PD-L1 IHC platform was performed on normal FFPE endocrine tissue samples stored in our hospital pathology tissue archive. Results: Five samples from each organ including pituitary, thyroid, parathyroid, adrenal and pancreas were examined. Focal membranous PD-L1 positivity was noted in the normal pituitary tissues, but was negative in normal thyroid, parathyroid, adrenal and pancreatic tissues. Conclusions: Majority of normal endocrine tissues do not demonstrate increased PD-L1 expression. Our limited data so far does not support the hypothesis that increased PD-L1 expression in endocrine tissues is associated with the endocrine irAEs following anti PD-1 therapy. The increased predilection of endocrinopathies in patients treated with anti PD-1 inhibitors seems to be via alternate pathways. Unless otherwise noted, all abstracts presented at ENDO are embargoed until the date and time of presentation. For oral presentations, the abstracts are embargoed until the session begins. Abstracts presented at a news conference are embargoed until the date and time of the news conference. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO. Endocrine Society 2019-04-30 /pmc/articles/PMC6550633/ http://dx.doi.org/10.1210/js.2019-MON-LB008 Text en Copyright © 2019 Endocrine Society https://creativecommons.org/licenses/by-nc-nd/4.0/ This article has been published under the terms of the Creative Commons Attribution Non-Commercial, No-Derivatives License (CC BY-NC-ND; https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Endocrine Disruption
Pollack, Rena
Kagan, Maayan
Dresner-Pollak, Rivka
Tzahi, Neuman
MON-LB008 PD-L1 Expression in Normal Endocrine Tissues
title MON-LB008 PD-L1 Expression in Normal Endocrine Tissues
title_full MON-LB008 PD-L1 Expression in Normal Endocrine Tissues
title_fullStr MON-LB008 PD-L1 Expression in Normal Endocrine Tissues
title_full_unstemmed MON-LB008 PD-L1 Expression in Normal Endocrine Tissues
title_short MON-LB008 PD-L1 Expression in Normal Endocrine Tissues
title_sort mon-lb008 pd-l1 expression in normal endocrine tissues
topic Endocrine Disruption
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6550633/
http://dx.doi.org/10.1210/js.2019-MON-LB008
work_keys_str_mv AT pollackrena monlb008pdl1expressioninnormalendocrinetissues
AT kaganmaayan monlb008pdl1expressioninnormalendocrinetissues
AT dresnerpollakrivka monlb008pdl1expressioninnormalendocrinetissues
AT tzahineuman monlb008pdl1expressioninnormalendocrinetissues